Quarterly ResultMay 14, 2026, 05:22 PM
Oncotelic Q1 Net Loss $(2.19)M; Strategic Robotics Partnership
AI Summary
Oncotelic Therapeutics reported a net loss of $(2.19) million for the first quarter of 2026, significantly wider than the $(0.29) million loss in Q1 2025. The company also disclosed a negative working capital of approximately $(16.3) million and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern. Despite financial challenges, Oncotelic entered a strategic partnership with TechForce Robotics to commercialize an AI-enabled, GMP-compliant robotics platform and continues development of its immuno-oncology therapeutics through its GMP Bio joint venture.
Key Highlights
- Net loss attributable to Oncotelic Therapeutics widened to $(2.19) million in Q1 2026 from $(0.29) million in Q1 2025.
- Total operating expenses increased to $1.85 million in Q1 2026 from $0.10 million in Q1 2025.
- The company reported negative working capital of approximately $(16.3) million as of March 31, 2026.
- Net cash used in operating activities was $(0.34) million in Q1 2026, compared to $(0.17) million in Q1 2025.
- Oncotelic entered a strategic partnership with TechForce Robotics for an AI-enabled, GMP-compliant robotics platform.
- The company secured $350,000 in proceeds from convertible debt during Q1 2026.
- Investment in GMP Bio at fair value remained stable at $388.0 million as of March 31, 2026.
- Issued 26,512 preferred shares for services and 1,600,446 common shares with warrants for debt in Q1 2026.